Stage IV marginal zone B-cell lymphoma - prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study

Title
Stage IV marginal zone B-cell lymphoma - prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study
Author(s)
김민경오성용[오성용]김원석[김원석]김진석[김진석]김석진[김석진]이수[이수]이대호[이대호]원종호[원종호]황인규[황인규]이순일[이순일]채이수[채이수]양덕환[양덕환]강혜진[강혜진]최철원[최철원]박지니[박지니]김효정[김효정]권정혜[권정혜]이호섭[이호섭]이경원[이경원]엄현석[엄현석]곽재용[곽재용]서철원[서철원]김효진[김효진]
Keywords
SINGLE-CENTER EXPERIENCE; DISEASE DISSEMINATION; CLINICAL ACTIVITY; HODGKINS-DISEASE; TISSUE LYMPHOMA; MALT LYMPHOMA; CLASSIFICATION; COMMITTEE; THERAPY
Issue Date
201009
Publisher
WILEY-BLACKWELL
Citation
CANCER SCIENCE, v.101, no.11, pp.2443 - 2447
Abstract
Stage IV marginal zone B-cell lymphomas (MZL) are detected in more than 25% of lymphoma patients. In this study, we conducted retrospective analyses of specific cases of stage IV MZL in order to assess their clinical features, as well as the treatments and prognoses of these cases. A total of 94 patients with histological diagnosis of stage IV-MZL from 17 different institutions in Korea were included. Multiple-mucosa-associated lymphoid tissue (MALT)-organs-involved MZL (M-MZL) was detected in 34 patients (36.2%). Bone-marrow-involved stage IV MZL (BM-MZL) was detected in 33 patients (35.1%). Median time to progression (TTP) was 2.4 years (95% CI, 1.9-2.9). Five- and 10-year overall survival rates were 84.5% and 79.8%, respectively. Patients with lymph node involvement in stage IV MZL appeared to have worse prognoses in TTP (P = 0.015). Thirty-one patients were treated with a regimen including rituximab (CTx-R[+]), and 31 with a regimen that did not include rituximab (CTx-R[-]). The CTx-R(+) group showed better responses than the CTx-R(-) group (83.9%versus 54.8%, P = 0.026). However, no differences in TTP duration were detected (P = 0.113). Stage IV MZL tend to follow an indolent disease course. Therefore, lymph node involvement is a more valuable prognostic factor for TTP. Rituximab appears to contribute to better responses, but not in cases of TTP. (Cancer Sci 2010; 101: 2443-2447).
URI
http://hdl.handle.net/YU.REPOSITORY/23640http://dx.doi.org/10.1111/j.1349-7006.2010.01698.x
ISSN
1347-9032
Appears in Collections:
의과대학 > 내과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE